[go: up one dir, main page]

RU2179848C1 - Application of antidepressant amitriptiline in patients with cancer of lung - Google Patents

Application of antidepressant amitriptiline in patients with cancer of lung Download PDF

Info

Publication number
RU2179848C1
RU2179848C1 RU2001108558/14A RU2001108558A RU2179848C1 RU 2179848 C1 RU2179848 C1 RU 2179848C1 RU 2001108558/14 A RU2001108558/14 A RU 2001108558/14A RU 2001108558 A RU2001108558 A RU 2001108558A RU 2179848 C1 RU2179848 C1 RU 2179848C1
Authority
RU
Russia
Prior art keywords
antidepressant
patients
lung
cancer
amitriptiline
Prior art date
Application number
RU2001108558/14A
Other languages
Russian (ru)
Inventor
С.Б. Марасанов
Original Assignee
Государственное учреждение Тверская государственная медицинская академия
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственное учреждение Тверская государственная медицинская академия filed Critical Государственное учреждение Тверская государственная медицинская академия
Priority to RU2001108558/14A priority Critical patent/RU2179848C1/en
Application granted granted Critical
Publication of RU2179848C1 publication Critical patent/RU2179848C1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FIELD: oncology. SUBSTANCE: antidepressant amitriptiline is applied as agent possessing antiallergic activity to correct allergic state in patients with cancer of lung. Agent allows one to refuse to administer two preparations (antiallergic agent and antidepressant) and thereby to avoid polypragmasia, to improve quality of patient's life, and to create positive pharmacoeconomical effect. EFFECT: simplified treatment and improved its quality.

Description

Изобретение относится к медицине, а именно к клинической фармакологии. The invention relates to medicine, namely to clinical pharmacology.

Цель изобретения - применение амитриптилина для противоаллергической терапии больных раком легкого. The purpose of the invention is the use of amitriptyline for antiallergic therapy of patients with lung cancer.

Для лечения и предупреждения паранеопластической аллергии в настоящее время используют антигистаминные препараты (блокаторы H1-рецепторов); препараты, тормозящие высвобождение и активность гистамина и других "медиаторов" аллергии (стабилизаторы мембран); антисеротонинные, анти-srs-А (медленно реагирующая субстанция апафилаксии) вещества; глюкокортикоиды; иммунодепрессанты (Большая медицинская энциклопедия. - М., 1974.-T.1. - С.284-286).For the treatment and prevention of paraneoplastic allergies, antihistamines (H 1 receptor blockers) are currently used; drugs that inhibit the release and activity of histamine and other "mediators" of allergies (membrane stabilizers); antiserotonin, anti-srs-A (slow-reacting apaphylaxis substance) substances; glucocorticoids; immunosuppressants (Big Medical Encyclopedia. - M., 1974.-T.1. - P.284-286).

Антидепрессанты, одновременно обладающие противоаллергическим действием, не описаны. Antidepressants that simultaneously have anti-allergic effects are not described.

Предлагается применение трициклического антидепрессанта амитриптилина для коррекции аллергического статуса больных раком легкого. The use of tricyclic antidepressant amitriptyline for the correction of the allergic status of patients with lung cancer is proposed.

Амитриптилин является одним из основных представителей трициклических антидепрессантов. Тимолептическое действие сочетается у амитриптилина с выраженным седативным эффектом. Препарат относительно широко применяется в соматической медицине при депрессивных и невротических состояниях (Машковский М.Д. Лекарственные средства. - Харьков, 1997. - T.1. - С.98-99). Amitriptyline is one of the main representatives of tricyclic antidepressants. The timoleptic effect is combined in amitriptyline with a pronounced sedative effect. The drug is relatively widely used in somatic medicine for depressive and neurotic conditions (Mashkovsky MD Drugs. - Kharkov, 1997. - T.1. - P.98-99).

Амитриптилин назначался внутрь по 0,0125 г 2 раза в день. Контрольное исследование аллергического статуса по данным реакции дегрануляции базофилов проводилось до и через 7 дней лечения амитриптилином. Amitriptyline was administered orally at 0.0125 g 2 times a day. A control study of allergic status according to the reaction of basophil degranulation was carried out before and after 7 days of treatment with amitriptyline.

По данным реакции дегрануляции базофилов (Тимашева Е.Д., Ковязина А.И.// Лаб.дел. - 1969. 3. - С.135-138) амитриптилин оказывал выраженное положительное влияние на больных. Спонтанная дегрануляция базофилов у больных раком легкого (5,4±0,14) была достоверно увеличенной (Р<0,05) по сравнению со здоровыми (2,4±0,1). According to the reaction of basophil degranulation (Timasheva E.D., Kovyazina A.I. // Lab.del. - 1969. 3. - P.135-138) amitriptyline had a pronounced positive effect on patients. Spontaneous degranulation of basophils in patients with lung cancer (5.4 ± 0.14) was significantly increased (P <0.05) compared with healthy ones (2.4 ± 0.1).

На фоне терапии амитриптилином обнаружена определенная закономерность в динамике спонтанной дегрануляции базофилов, которая проявилась достоверным ослаблением этой реакции в конце лечения препаратом (2,7±0,15; Р<0,05). On the background of amitriptyline therapy, a certain pattern was found in the dynamics of spontaneous degranulation of basophils, which was manifested by a significant weakening of this reaction at the end of drug treatment (2.7 ± 0.15; P <0.05).

Таким образом, по данным проведенных исследований можно сделать вывод, что антидепрессант амитриптилин обладает не только тимолептическим и седативным действием, но и оказывает противоаллергический эффект. Полученные данные могут быть использованы у больных с различной локализацией опухоли. Преимущество предложенного метода противоаллергической терапии заключается в том, что назначение антидепрессанта амитриптилина, обладающего противоаллергическим действием, позволяет отказаться от назначения двух препаратов (противоаллергического и антидепрессанта) и тем самым избежать полипрагмазии, улучшить качество жизни больных, создать положительный фармакоэкономический эффект. Thus, according to the data of the conducted studies, it can be concluded that the antidepressant amitriptyline has not only a timoleptic and sedative effect, but also has an anti-allergic effect. The data obtained can be used in patients with different localization of the tumor. The advantage of the proposed method of antiallergic therapy is that the appointment of amitriptyline antidepressant, which has an antiallergic effect, allows you to refuse the appointment of two drugs (antiallergic and antidepressant) and thereby avoid polypharmacy, improve the quality of life of patients, create a positive pharmacoeconomic effect.

Claims (1)

Применение антидепрессанта амитриптилина у больных раком легкого в качестве средства, обладающего противоаллергическим действием, для коррекции аллергического статуса. The use of the antidepressant amitriptyline in patients with lung cancer as an anti-allergic drug to correct allergic status.
RU2001108558/14A 2001-03-30 2001-03-30 Application of antidepressant amitriptiline in patients with cancer of lung RU2179848C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2001108558/14A RU2179848C1 (en) 2001-03-30 2001-03-30 Application of antidepressant amitriptiline in patients with cancer of lung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2001108558/14A RU2179848C1 (en) 2001-03-30 2001-03-30 Application of antidepressant amitriptiline in patients with cancer of lung

Publications (1)

Publication Number Publication Date
RU2179848C1 true RU2179848C1 (en) 2002-02-27

Family

ID=20247842

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001108558/14A RU2179848C1 (en) 2001-03-30 2001-03-30 Application of antidepressant amitriptiline in patients with cancer of lung

Country Status (1)

Country Link
RU (1) RU2179848C1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2239441C1 (en) * 2003-08-13 2004-11-10 Государственный Научный Центр социальной и судебной психиатрии им. В.П.Сербского Method for treatment of patient with neurotic and somatoformic disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2051672C1 (en) * 1988-10-24 1996-01-10 Волгоградский медицинский институт Agent showing antidepressant and nootropic activity
RU2125553C1 (en) * 1992-01-16 1999-01-27 Хехст АГ Arylcycloalkyl derivatives and pharmaceutical compositions based thereof
RU2138486C1 (en) * 1993-06-29 1999-09-27 Ниссан Кемикал Индастриз Лтд. Derivatives of 3(2h)-pyridazinones or their pharmaceutically acceptable additive acid salts and pharmaceutical composition on said

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2051672C1 (en) * 1988-10-24 1996-01-10 Волгоградский медицинский институт Agent showing antidepressant and nootropic activity
RU2125553C1 (en) * 1992-01-16 1999-01-27 Хехст АГ Arylcycloalkyl derivatives and pharmaceutical compositions based thereof
RU2138486C1 (en) * 1993-06-29 1999-09-27 Ниссан Кемикал Индастриз Лтд. Derivatives of 3(2h)-pyridazinones or their pharmaceutically acceptable additive acid salts and pharmaceutical composition on said

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHU J et al. Effect of monoamine reuptake inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis, Immunopharmacology, 1994, May-Jun, 27(3): 225- 44. SANGER MD. The treatment of anxiety and depression in the allergic patient, Ann Allergy, 1969, Oct; 27(10): 506-10. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2239441C1 (en) * 2003-08-13 2004-11-10 Государственный Научный Центр социальной и судебной психиатрии им. В.П.Сербского Method for treatment of patient with neurotic and somatoformic disorders

Similar Documents

Publication Publication Date Title
ES2992838T3 (en) Treatment of irritability in autism spectrum disorder with cannabidiol
BRPI0512075A (en) compound, process for the preparation thereof, pharmaceutical composition, use of a compound, and methods for producing a b-raf inhibiting effect, and an anticancer effect on a warm-blooded animal, and for treating a disease
WO2020263980A8 (en) IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
BRPI0111591B8 (en) compound, pharmaceutical composition, and uses of a compound
AR068901A1 (en) USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS AFFECTED BY COGNITIVE DISORDERS
TW201309298A (en) Pharmaceutical composition for treating malignant glioma
CN108586443B (en) A kind of drug and preparation method thereof for preventing and treating lung bronchogenic carcinoma
RU2179848C1 (en) Application of antidepressant amitriptiline in patients with cancer of lung
CN110755432A (en) Application of nicotinamide in preparation of preparation for treating hand-foot skin reaction
US11369619B2 (en) Composition for curing migraine headaches
CA3262238A1 (en) Use of manganese-containing compounds in reducing uric acid levels in mammalian individuals
Maheshwari et al. Methylene Blue in Septic Shock: Emerging Evidence, Clinical Applications, and Future Directions
ZA202311237B (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
Tankl et al. To evaluate role of gabapentin as a preemptive analgesic in the patients undergoing modified radical mastectomy
CN105963287B (en) Compound and its medical usage
CN110882240A (en) Polyphenol derivative compound 6-CEPN as therapeutic agent for acute ischemic stroke
CN111346093B (en) Application of combination of lamivudine and domperidone in preparation of sedative drugs
TW201136928A (en) Treatment of dementia of Alzheimer&#39;s type with masitinib
Pd Oxcarbazepine-induced toxic epidermal necrolysis: A case report
CN107375422A (en) Treatment part catarrh symptom liniment and preparation method thereof
RU2296567C1 (en) Method for chemoradiation therapy of brain malignant glial tumor
RU2293565C2 (en) Method for treating cerebral lesions
RU2564905C1 (en) Method of treating patients with localised scleroderma
US8252801B1 (en) Treatment of schizophrenia and related disorders
RU2334515C2 (en) Application of &#34;day&#34; tranquilliser phenibute and anti-depressant - selective inhibitor of serotonin re-uptake trittico during treatment of psoriasis

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20050331